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Fascin-1 enhances experimental
osteosarcoma tumor formation and
metastasis and is related to poor patient
outcome
Matthias J. Arlt1, Aleksandar Kuzmanov2, Jess G. Snedeker1, Bruno Fuchs3, Unai Silvan1 and Adam A. Sabile1*
Abstract
Background: Fascin-1, a prominent actin-bundling protein, is found to be upregulated in several human
carcinomas. While it is accepted that Fascin-1 expression correlates with poor clinical outcome and decreased
survival in various carcinomas, its role in sarcoma such as osteosarcoma (OS) remains unknown. In the present
study, we evaluated the prognostic value and biological relevance of Fascin-1 in OS.
Methods: The correlation between Fascin-1 expression and the outcome of OS patients was determined by
immunohistochemistry analysis of Fascin-1 expression in a tissue microarray of OS tissue specimens collected
during primary tumor resection. To examine the effect of Fascin-1, shRNA and overexpression technology to alter
Fascin-1 levels in OS cells were used in cellular assays as well as in intratibial xenograft OS models in SCID mice.
Results: Kaplan-Meier survival analysis of Fascin-1 expression in OS tumor specimens revealed a direct relationship
between Fascin-1 expression and poor patient survival. Furthermore, overexpression of Fascin-1 in OS cells significantly
increased their migratory capacity as well as the activity of the matrix metalloprotease MMP-9, known to be critical for
the execution of metastasis. Finally, using relevant xenograft mouse models, orthotopic intratibial transplantation of
two different OS cell lines overexpressing Fascin-1 promoted tumor growth and lung metastasis.
Conclusions: Collectively, our findings demonstrate for the first time that Fascin-1 has considerable potential as a
novel prognostic biomarker in OS, and suggest that targeting of Fascin-1 might be a new anti-metastatic strategy in
OS patient treatment.
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Background
Osteosarcoma (OS) is the most frequent primary bone
cancer in childhood and has high propensity for metasta-
sis, the major cause of cancer-related death [1, 2]. At the
time of diagnosis, 20% of OS patients present detectable
metastasis, and in the absence of chemotherapy more than
60% of those with localized disease develop metastases
later on [3]. Despite the significant advances in OS treat-
ment, patients with metastases still have a long-term sur-
vival rate below 20% [4]. Therefore, identification of novel
therapeutic targets remains extremely important to pre-
vent metastasis and treat OS.
Metastasis is a complex multistep process in which
tumor cells implement a variety of migratory and invasive
strategies in order to infiltrate the primary tissue and dis-
seminate to distant sites. To succeed in cancerous spread-
ing, malignant cells undergo a number of phenotypic
adaptations, among which the reorganization of the actin
cytoskeleton is critical. It is known that the regulation of
the cell cytoskeleton is driven by a collective set of actin
binding proteins, which mediate the organization of actin
filaments into supramolecular arrangements [5]. A main
class of actin binding proteins is the Fascin family, which
comprises Fascin-1, − 2, and− 3. Fascin-1, the most
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ubiquitously expressed family member, regulates adhesion
dynamics and crosslinks actin microfilaments into tight and
parallel bundles. These bundles are important for the ex-
tension of filopodia and invadopodia and for the functional-
ity of these protrusions in promoting cell migration [6–8].
Fascin-1 is absent in most normal epithelia, but is highly
upregulated in several human carcinomas, and its expres-
sion levels correlate with more aggressive tumors and me-
tastasis [9, 10]. Furthermore, the upregulation of Fascin-1
in a number of carcinomas has been associated with worse
clinical outcome, poor prognosis, and shorter survival, indi-
cating that Fascin-1 may play a central role in tumorigen-
esis and metastasis [11–16]. However, its role in sarcoma
and in particular OS has not been described so far. In the
present study we have evaluated the prognostic value of
Fascin-1 and investigated its regulatory function in OS
tumorigenesis and metastasis.
Using a combined immunohistochemistry-based tissue
microarray (TMA) and Kaplan-Meier survival analysis
with tumor tissue specimens collected from OS patients,
we demonstrate that Fascin-1 expression correlates with
poor patient survival and can be used as an additional
prognostic factor for OS patient outcome. Furthermore,
with the aim of investigating its potential regulatory ef-
fect, in vitro manipulation of Fascin-1 expression by loss
or gain of function demonstrated an important role of
Fascin-1 in OS cell motility. In addition, we show that
Fascin-1 might facilitate the invasive process by
up-regulating MMP-9 activity. Finally, by making use of
intratibial xenograft OS mouse models, we showed that
overexpression of Fascin-1 in both osteoblastic and
osteolytic OS cell lines accelerated the growth of intra-
tibial xenografts and promoted lung metastasis. These
results clearly indicate a key role of Fascin-1 in OS pro-
gression and metastasis. Altogether, the results reported
here point to a great potential of Fascin-1 as a novel
prognostic marker as well as a possible target for thera-
peutic intervention in OS.
Methods
Human OS tissue microarray, Fascin-1 immunostaining
and Kaplan-Meier analysis
Osteosarcoma and normal bone tissue specimens were col-
lected between June 1990 and December 2005 from 67 pa-
tients during primary tumor resection in accordance with
the regulations of the local Swiss Ethic committee. The
clinical characteristics of the OS patients are presented in
Table 1. Among the 67 patients’ cohort, 53 received
complete neoadjuvant chemotherapy and the subsequent
response was determined histologically on resected tumor
specimens according to Salzer-Kuntschik [17]. Salzer-
Kuntschik grades I, II, and III were considered to be a good
response, whereas grades IV, V, and VI were classified as
non-responders. The TMA was constructed and processed
as previously described [18, 19], stained with anti-Fascin-1
mouse monoclonal antibody (1400; DAKO), and counter-
stained with hematoxylin. The grading of Fascin-1 immu-
nostaining was determined based on the intensity and the
percentage of the stained area. The percentage of staining
was calculated with a custom made MATLAB (v2009b,
Mathworks Inc) program as described [20]. Positive stained
(brown) and non-stained area (blue) were separated by
color deconvolution algorithm [21]. The area percentage of
the stain was defined as the positive stained area (number
of brown pixels) over total tissue area (number of blue and
brown pixels). Grade 1 (non or weak staining) was consid-
ered as negative and grades 2 and 3 (moderate and intense
staining) were considered as positive for Fascin-1 expres-
sion. A Kaplan-Meier analysis was used to correlate
Fascin-1 expression with overall survival of the patients.
Cell culture, shRNA constructs and retroviral transduction
Human SaOS-2 (ATCC® HTB85™) and 143B (ATCC®
CRL-8303™) OS cells, purchased from American Type
Culture Collection (ATCC; Manassas, USA), were cul-
tured in DMEM (4.5 g/l glucose)/HamF12 (1:1) medium
Table 1 Clinical characteristics of Osteosarcoma patients
Patients (n = 67) n (%)
Gender
Male 45 67
Female 22 33
Age (years)
< 10 8 12
10–19 34 51
20–29 15 22
30–39 6 9
≥ 40 4 3
Tumor type
Osteoblastic 43 64
Chondroblastic 14 21
Fibroblastic 6 9
Telangiectatic 4 6
Anatomic site
Extremities 57 85
Axial (pelvis or spine) 10 15
Metastasis
Total metastasis 24 36
Present at diagnosis 5 7
Metastasis after diagnosis 19 28
Chemotherapy response
Responders (*SK I-III) 30 57
Non-responders (SK IV-VI) 23 43
*SK: Salzer-Kuntschik
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(Invitrogen) supplemented with 10% heat inactivated
fetal bovine serum (FBS, Gibco) at 37 °C in a humidified
atmosphere of 5% CO2. SaOS-2 and 143B cells were sta-
bly transduced with a LacZ gene and selected to obtain
SaOS-2-LacZ and 143B-LacZ cell lines as previously re-
ported [22]. SaOS-2-LacZ and 143B-LacZ cells stably
over-expressing Fascin-1 (SaOS-2/Fascin-1 and 143B/
Fascin-1) were then obtained by transduction with
pLenti6/V5-DEST-FASCIN (a gift from Lynda Chin;
Addgene plasmid # 31207) and subsequent selection
with Blasticidin (Invitrogen, Carlsbad, CA, USA). Con-
trol SaOS-2-LacZ or 143B-LacZ cells were obtained by
transduction with empty pLentiV5-DEST.
To achieve Fascin-1 silencing, we tested 5 different
shRNA sequences cloned into the pLKO.1 retroviral vec-
tor (FSCN1 MISSION shRNA; Sigma-Aldrich). After
transduction of SaOS-2-LacZ and 143B-LacZ cells,
Puromycin resistant cells were selected. The efficiency of
Fascin-1 silencing was examined on Western blot, and
the most efficient oligonucleotide sequence 5’-CCGG
CCCTTGCCTTTCAAACTGGAACTCGAGTTC
CAGTTTGAAAGGCAAGGGTTTTTG-3′ was selected
and used in the subsequent experiments. pLKO.1 retro-
viral vector containing a scrambled oligonucleotide se-
quence was used as control. All generated stable cell
lines were authenticated by short tandem repeat DNA
profiling (Microsynth) with a PowerPlex®16HS system
(Promega) and by comparison with the German Collec-
tion of Microorganisms and Cell Cultures database
(DSMZ).
Immunofluorescence and image analysis
Cells grown on glass coverslips were fixed with 3.7% for-
maldehyde in phosphate-buffered saline (PBS) at room
temperature (RT) for 15min and permeabilized with 0.2%
Triton X-100 for 10min. After incubation at RT for 30
min with blocking solution (0.1% FBS in PBS), the cells
were incubated with specific primary antibodies in block-
ing solution at RT for 1 h. After 3 washing steps with PBS,
cells were incubated with fluorescently-labelled secondary
antibodies for 45min at RT. Primary antibodies used were
directed against Fascin-1 (1:400; DAKO) and V5 antibody
(1:5000; Invitrogen). Filamentous actin was stained by
means of Alexa-633-phalloidin and nuclei using NucBlue
(Invitrogen). Secondary antibodies were Alexa-Fluor488
conjugated donkey anti-mouse or Alexa-Fluor488 conju-
gated donkey anti-rabbit (Life Technologies). Immuno-
fluorescent cells were visualized using a spinning disc
confocal microscope (iMic, TILL Photonics) equipped
with a 60X N.A. 1.35 lens. For the morphological analysis,
we used the Cell Profiler software to estimate the perim-
eter and spreading area of each individual cell [23]. We
then used these values to calculate the ratio between them
using the formula: R = perimeter * 100 / area.
Wound-healing migration assay
The migratory properties of OS cells were assessed in a
wound healing migration assay. Cells were seeded into
24-well plates. At confluency, wounds measuring be-
tween 0.5 and 1mm in width and approximately 1 cm in
length were created with a sterile pin. After 3 washing
steps with PBS to remove detached cells and cell debris,
the wounds were marked with a Nikon object marker at-
tached to a Nikon Diaphot microscope. Photos of the
marked wounds were taken immediately after wounding
and after incubation at 37 °C for 16 h. The width of the
marked wound areas were measured with the ImageJ
Software and the migration rate (μm/h) was then calcu-
lated as described [24].
Zymography and Western blot analysis
The gelatinase activity of MMP2 and MMP9 was analyzed
by means of collagen zymography as previously described
[25]. For western blot analysis, cells were lysed in ice-cold
50mM Tris, pH 7.5 containing 250mM NaCl, 5 mM
EDTA, 0.5% NP-40, 50mM NaF, 0.2 mM Na3VO4, 1 mM
dithiothreitol (DTT), 1 mM phenylmethylsulphonyl fluo-
ride (PMSF), and 10mg/ml aprotinin. Cell lysates were
cleared by centrifugation and protein concentrations de-
termined with a Bio-Rad assay (Bio-Rad Laboratories,
Hercules, CA, USA). Endogenous and V5-tagged Fascin-1
protein and GAPDH were detected using mouse mono-
clonal Fascin-1 (1:1000; DAKO), V5 antibody (1:5000;
Invitrogen), and rabbit polyclonal anti-GAPDH antibody
(1:5000; Santa Cruz Biotechnologies) and corresponding
horseradish peroxidase-conjugated secondary antibodies
(Santa Cruz Biotechnologies). Peroxidase activity was visu-
alized with the Immobilon chemiluminescence substrate
(Millipore, Billerica, MA, USA) and detected with Image
Lab System (Bio-Rad, Hercules, CA, USA).
Human osteosarcoma xenograft mouse model
All animal experiments were performed according to the
institutional guidelines and approved by the Ethics Com-
mittee of the Veterinary Department, Canton of Zurich,
Switzerland. Specific pathogen-free female SCID mice
obtained from Charles River (Sulzfeld, Germany) were
housed for at least 2 weeks before commencement of the
study and then randomly divided into four groups of 12
mice each. As described previously [19], after anesthesia
of the mice with a mixture of Fentanyl, Midazolam, and
Medetomidin, 10 μl of PBS containing 105 cells was
injected into the medullar cavity of the left tibia. The
health status of the mice was monitored three times a
week and primary tumor growth was monitored weekly
by X-ray. The tumor volume was calculated from caliper
measurements of the tumor-bearing leg and the healthy
control leg by the equation: length × (width)2 / 2 of the
tumor bearing tibia minus length × (width)2 / 2 of the
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control tibia. At the end of the study, the mice were
anaesthetized with a mixture of Ketamine, Xylazine, and
Acepromazine. Then, the mice were sacrificed by re-
moval of the blood from the cardiovascular system using
PBS perfusion into the right ventricle of the beating heart,
and the lungs were prepared. For the LacZ gene expression,
the fixed organs were stained with 5-bromo-4-chloro-
3-indolyl-β-D-galactoside (X-Gal) solution at 37 °C for at
least 3 h as described [22]. Metastases in individual lungs,
visible as blue-stained foci, were then quantified by manual
counting under the microscope.
Statistical analysis
Results of the in vivo experiments are presented as
mean ± standard error of the mean (SEM), and quantifi-
cation results of the Western blots are presented as the
mean ± standard deviation (SD). Differences between
means were analyzed for significance by unpaired t-test
with GraphPad Prism® 5.01 software. The Kaplan–Meier
analysis was statistically analyzed with the log-rank test.
p < 0.05 was considered statistically significant.
Results
Fascin-1 expression correlates with poor overall survival
of the patients
To identify effector molecules involved in OS metastasis,
we performed combined immunohistochemistry-based
TMA and Kaplan-Meier survival analysis. Human OS
TMA sections including tumor specimens collected
from 67 patients during primary tumor resection were
analyzed immunohistochemically for Fascin-1 expres-
sion, among them twenty-four patients had metastatic
disease (Table 1). Representative images of tissue micro-
array sections with non-detectable, weak, moderate and
intense Fascin-1 immunostaining are presented in
Fig. 1a.
A Kaplan-Meier survival analysis showed that, irre-
spective of local or metastatic disease, patients with
Fascin-1 positive expression in tumor tissues had a sig-
nificantly (p < 0.01) shorter overall survival than those
with non-detectable Fascin-1 expression (Fig. 1b).
A second Kaplan-Meier survival analysis distinguish-
ing between patients with local or with metastatic dis-
ease, revealed that patients with metastases and positive
immunostaining for Fascin-1 exhibited a significantly
shorter survival than those with metastases and Fascin-1
negative tumors (p < 0.05) (Fig. 1c). In the cohort with
local disease no significant difference in the survival time
was present between patients with Fascin-1 positive tumors
and those that were Fascin-1 negative. In a further
Kaplan-Meier analysis correlating Fascin-1 expression with
the response to neoadjuvant therapy, non-responders who
were Fascin-1-positive tended to have a shorter overall
survival than Fascin-1-negative non-responders although
the difference was not statistically significant (p = 0.1069,
Additional file 1: Figure S1). Since the lack of statistical sig-
nificance was likely related to the small number of patients,
this finding nevertheless implicate that Fascin-1 might be
associated with worse outcome in subsets of OS patients
who responded poorly to chemotherapy. All findings taken
Fig. 1 Kaplan-Meier analysis correlating immunohistochemical staining of Fascin-1 in human OS tissues with overall survival of the patients. (A)
Representative images of TMA sections showing entire spots (upper panel) and higher magnification (lower panel) with non-detectable (a), weak
(b), moderate (c), and intense (d) Fascin-1 immunostaining. (B) Overall survival of OS patients with non-detectable (Fascin-1 neg) or detectable
(Fascin-1 pos) immunostaining of tumor tissues. (C) Overall survival of patients without (Mets neg) or with (Mets pos) metastases and Fascin-1
neg or Fascin-1 pos tumors
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together imply that the expression of Fascin-1 in OS
tumors correlates with a poor prognosis for the patients,
and consequently might be considered as new potential
predictor for OS outcome.
Overexpression of Fascin-1 increases cell migration and
MMP9 activity
In order to assess the function of Fascin-1 in OS and to ac-
count for the heterogeneity in phenotypes of OS [26], we
used one osteoblastic (SaOS-2) and one osteolytic cell line
(143B) and generated from those cell lines stably overex-
pressing Fascin-1 or with silenced Fascin-1 as described in
the methods section. The levels of V5-Fascin-1 expression
and the silencing efficiency were determined by western
blot (Fig. 2a).
Since Fascin-1 is associated with the initiation and forma-
tion of filopodia structures, we considered whether
Fascin-1-silencing or overexpression in OS cells may affect
filopodia formation. As expected, independently of the type
of the cell line, silencing of Fascin-1 was accompanied by a
slight decrease in the ratio of cell perimeter by spreading
area, suggesting reduced protrusion potential (Fig. 2b and
c). Interestingly, Fascin-1 overexpression did not cause de-
tectable differences in comparison to the wild type.
Based on the results of the Kaplan-Meier analyses, we
speculated that Fascin-1 expressed by OS tumors may
be a stimulatory factor in the regulation of metastatic
activity. Consequently, we compared wound-healing mi-
gration of SaOS-2 and 143B cells stably overexpressing
V5-tagged Fascin-1 (SaOS-2/Fascin-1 and 143B/Fas-
cin-1) with that of empty vector transfected SaOS-2
(SaOS-2/EV) and 143B (143B/EV) control cells with low
expression of endogenous Fascin-1. The migration rate
of SaOS-2/Fascin-1 cells was 2 times (p < 0.01) higher
than that of control SaOS-2/EV cells, while silencing of
Fascin-1 decreased moderately the migration rate
(p < 0.05) (Fig. 3a). Similar results were obtained with
143B cells, where Fascin-1 overexpression increased
the migration rate by 2.5 folds in comparison to control
EV cells (p < 0.01), and silencing of Fascin-1 slightly de-
creased the migratory rate (p < 0.05) (Fig. 3b). It is note-
worthy that Fascin-1 did not affect the proliferation
of SaOS-2 and 143B cells in vitro. The calculated
doubling times and the percentage of proliferating
cells, assessed by immunostaining for the proliferation
marker Ki67, were indistinguishable in cultures of
cells overexpressing Fascin-1 and control cells (not
shown).
Fig. 2 Validation and characterization of OS cell lines with altered Fascin-1 expression. (a) Western blot analysis with antibodies to Fascin-1 (top
panel), to V5 (middle panel), and to GAPDH as a loading control (lower panel) of protein extracts from SaOS-2 (left panel) and 143B (right panel)
cells stably transduced with a scrambled control ShRNA (Ctrl ShRNA), a Fascin-1-specific ShRNA (ShFascin-1), a pLenti6/V5-DEST empty vector (EV),
or pLenti6/V5-DEST-Fascin-1 (Fascin-1). (b) SaOS-2/WT (upper row), SaOS-2/Fascin-1 (middle row), and SaOS-2/ShFascin-1 (bottom row) cells
stained with anti-Fascin-1 (green), with Alexa-633-phalloidin (filamentous actin, red), and with NucBlue (nuclei in blue). (c) While silencing Fascin-1
reduces the perimeter of the cells in both cases, overexpression has little impact (n = 34–57)
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Furthermore, we tested whether Fascin-1 enhances the
activity of some mediators of metastasis such as MMP-2
and MMP-9, which are among the most well established
proteases known to degrade the extracellular matrix and
facilitate invasion and metastasis. In contrast to MMP-2,
which shows equivalent activity in all studied conditions,
up-regulation of Fascin-1 increased significantly the
MMP-9 activity compared to the EV control cells (Fig. 3c).
Fascin-1 enhances intratibial primary tumor growth and
pulmonary metastasis in two different xenograft OS
mouse models
To study the impact of Fascin-1 on tumor growth and
spreading in a physiologically faithful microenvironment,
we performed orthotopic transplantation of OS cell lines
into the tibia of SCID mice. Orthotopic tumors derived
from injected SaOS-2 cells are mainly osteoblastic, re-
sembling the osteogenic tumor phenotype in humans
[19, 27], while, upon intratibial injection of 143B cells,
the resulting primary tumors are predominantly osteo-
lytic, thereby representing the osteolytic OS cases seen
in human patients [28]. Irrespectively of the phenotype
of the used OS cells, the generated experimental tumors
preferentially metastasize in lungs. Thus, these orthoto-
pic mouse models reflect more closely the clinical
pattern than intravenous injection or subcutaneous im-
plantation of OS tumor cells [29]. To assess the effect of
Fascin-1 on OS malignancy we compared the tumori-
genic and metastatic potential of SaOS-2-LacZ and
143B-LacZ cells over- and under-expressing Fascin-1. As
shown in Fig. 4, mice injected with SaOS-2/Fascin-1
cells developed fast growing primary tumors six weeks
after injection and showed osteoblastic lesions in the
bone and the surrounding soft tissue (Fig. 4a, lower
panel). In contrast, in mice injected with SaOS-2/EV cells,
primary tumors remained radiologically undetectable until
week eight (Fig. 4a, upper panel). Mice of both SaOS-2/Fas-
cin-1 and SaOS-2/EV groups were sacrificed after 10weeks
because the animals in the SaOS-2/Fascin-1 group became
moribund. Accordingly to the X-ray monitoring, Fascin-1
xenografts with a final mean primary tumor volume of 145
± 25.8mm3 (SaOS-2/Fascin-1) were significantly (p < 0.05)
larger than SaOS-2/EV (43.2 ± 3.5mm3) xenografts (Fig. 4c).
Similarly, the calculated mean primary tumor volume
(356.4 ± 40.1mm3) of 143B/Fascin-1 xenografts were signifi-
cantly (p < 0.05) bigger (137.8 ± 34.6mm3) than 143B/EV xe-
nografts (Fig. 5a and c). Moreover, the ex vivo X-gal-staining
of lung whole mounts revealed that SaOS-2/Fascin-1 and
143B/Fascin-1 cells generated an average number of meta-
static lesions 2.5 and 2 times larger than wild type cells
Fig. 3 Migration assessed by wound healing. Overexpression of Fascin-1 in SaOS-2 (a) or in 143B (b) OS cells increases significantly the migration
ability. Similarly, silencing of Fascin-1 slightly decreased the migratory rate of SaOS-2 (a) and 143B (b) cells. Results are the mean ± SEM of at least
three independent experiments. (c) Zymography analysis showing increased MMP-9 activity in SaOS-2/Fascin-1 (left panel) and in 143B/Fascin-1
(right panel) in comparison to control SaOS-1/EV and 143B/EV cells respectively. Results are the mean ± SEM of three independent experiments
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Fig. 4 Fascin-1 overexpression in SaOS-2 cells promotes intratibial primary tumor growth and lung metastasis in SCID mice. (a) Representative X-ray
images of tumor-bearing hind limbs of mice injected with SaOS-2/EV cells (upper panel) or with SaOS-2/Fascin-1 (lower panel). The images show
primary tumor appearance on indicated days after tumor cell injection. (b) Representative X-ray images of tumor-bearing hind limbs of mice
injected with SaOS-2/Ctrl ShRNA cells (upper panel) or with SaOS-2/ShFascin-1 cells (lower panel). (c) Mean primary tumor growth over time in
mice intratibially injected with SaOS-2/EV cells (black), with SaOS-2/Fascin-1 cells (red), with SaOS-2/Ctrl ShRNA (grey) or with SaOS-2/ShFascin-1
blue). (d) Mean number ± SEM of metastatic lesions in the lungs
Fig. 5 Fascin-1 overexpression in 143B cells promotes intratibial primary tumor growth and lung metastasis in SCID mice. (a) Representative X-ray
images of tumor-bearing hind limbs of mice injected with 143B/EV cells (upper panel) or with 143B/Fascin-1 (lower panel). The images show
primary tumor appearance on indicated days after tumor cell injection. (b) Representative X-ray images of tumor-bearing hind limbs of mice
injected with 143B/Ctrl ShRNA cells (upper panel) or with 143B/ShFascin-1 cells (lower panel). (c) Mean primary tumor growth over time in mice
intratibially injected with 143B/EV cells (black), with 143B/Fascin-1 cells (red), with 143B/Ctrl ShRNA (grey) or with 143B/ShFascin-1 blue).
(d) Quantification of the number of metastatic lesions in lungs
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respectively (Fig. 4d and 5d). It is noteworthy that silencing
of Fascin-1 in both SaOS-2 and 143B cell line systems did
not significantly affect neither primary tumor growth (Fig.
4b/c and Fig. 5b/c respectively), nor metastasis formation
(Fig. 4d and 5d respectively). However, although not statisti-
cally significant, the metastatic potential of ShFascin-1 in
143B cells was nearly 40% lower than control cell (Fig. 5d).
Taken together, our data demonstrates for the first time that
Fascin-1 enhances primary tumor formation and promotes
lung metastasis in OS.
Discussion
Our study demonstrates that Fascin-1 expression signifi-
cantly correlates with OS progression and metastasis,
suggesting Fascin-1 as a potential prognostic biomarker
for poor outcome of OS patients.
Osteosarcoma is the most frequent primary bone cancer
in childhood with high propensity for metastasis, the major
cause of cancer-related death [1, 2]. Therefore, understand-
ing the molecular basis of OS progression, especially during
invasion and metastasis, and the identification of potential
prognostic and predictive biomarkers and therapeutic tar-
gets for OS treatment are required to refine treatment and
to improve the currently poor patient outcome. In an effort
to identify valuable regulatory biomarkers, we used
high-throughput tissue microarray and immunohistochem-
istry with antibodies against a panel of regulatory mole-
cules. With this approach, we identified and selected
Fascin-1 for further investigation. Indeed, it is known that
the acquisition of invasive and metastatic potential of
tumor cells is associated with the reorganization of the
actin cytoskeleton. In this regard, Fascin-1, an actin binding
protein that crosslinks actin filaments into bundles appears
up-regulated in some carcinomas and has been previously
proposed as a therapeutic biomarker [10, 16, 30, 31]. How-
ever, the biological relevance of Fascin-1 expression in OS
progression and metastasis is not reported up to date.
Therefore, we have explored Fascin-1 as a potential prog-
nostic marker for OS.
The Kaplan-Meier survival analysis revealed a signifi-
cant correlation between Fascin-1 expression and poor
patient prognosis. Furthermore, the analysis confirmed
the well-documented clinical observation that mortality
of OS patients is manly caused by metastasis of the pri-
mary tumor. However, our data also showed that
Fascin-1 expression in primary tumors defines a sub-
group within the metastatic disease cohort with signifi-
cantly worse prognosis, indicating an important role of
Fascin-1 in this life-threatening step of OS progression.
These findings are in line with the results reported for
carcinomas [10, 32–34].
Furthermore, we overexpressed and silenced the expres-
sion of Fascin-1 gene in SaOS-2 and 143B cells and studied
their impact in vitro and in vivo in an intratibial xenograft
OS model in SCID mice. Because Fascin-1 is best known
for its function as actin cytoskeleton organizer, we first in-
vestigated its impact on actin-related processes, namely, cell
morphology and motility. Image analysis of wild type and
OS cells with silenced or overexpressed Fascin-1, revealed
that while silencing of Fascin-1 does reduce the amount of
membrane protrusions, overexpression does not have a sig-
nificant impact on cell shape. Because Fascin-1 requires
post-translational modifications for its filopodial-stabiliza-
tion function, it is possible that in OS cells overexpression
of Fascin-1 is insufficient to cause a significant increase in
these protrusions [35, 36]. In turn, wound healing assays re-
vealed increased migration velocities in OS cells overex-
pressing Fascin-1, while the impact of Fascin-1 repression
was not significant.
Besides its structural functions, Fascin-1 is as well
known to participate in other cellular processes, including
transcriptional regulation [37]. In this regard, our experi-
ments revealed that forced expression of Fascin-1 in OS
cell lines enhances MMP9 secretion and activity. Because
augmented cell motility and protease activity contribute to
the cascade that leads to metastasis, these findings under-
score the importance of Fascin-1 expression in the malig-
nant progression of OS, and are in line with the results
reported for other cancers [10, 34, 38, 39].
Our study also revealed that OS cells overexpressing
Fascin-1 show a markedly enhanced in vivo malignant
phenotype compared to control cells in intratibial xenograft
OS mouse models. This was evidenced by accelerated
primary tumor growth, and higher percentage of metastatic
lesions of the mice injected with cells overexpressing
Fascin-1 compared with the animals that received control
cells. These observations are in good agreement with the
results reported for carcinomas [40, 41]. However, despite
the strong effect of Fascin-1 overexpression, silencing of
Fascin-1 did affect neither primary tumor formation, nor
metastasis formation in our intratibial xenograft models.
This finding is different to the results described in carcin-
omas such as colon adenocarcinoma or esophageal squa-
mous cell carcinoma. When invasiveness of cells isolated
from these epithelial tumors were analyzed in mouse xeno-
graft models, silencing of Fascin-1 results in decreased pri-
mary tumor growth [42–44]. It is however noteworthy that
these animal studies employed heterotopic xenograft mouse
models with subcutaneous cell inoculation, as opposed to
our in vivo study in which we performed orthotopic (intra-
tibial) tumor cell injection, which takes into account the
tumor microenvironment. It is well-documented that the
dynamic crosstalk between tumor cells and the local micro-
environment critically influences their ability for migration,
invasion, and metastasis [45]. Otherwise, as it is well
acknowledged that functionally related proteins cooperate
to achieve their function, one could speculate that some
other factors might functionally interact with Fascin-1, and
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thereby Fascin-1 silencing could be compensated by these
proteins. Indeed, the actin bundling factor Daam1 and
L-plastin were shown to functionally cooperate with
Fascin-1 in the stabilization of invadopodia and filopodia in
cancer cells [46, 47]. The fact that Fascin-1 homozygous
KO mice are viable and fertile [48], further supports the
idea that other factors compensate the absence of Fascin-1.
Conclusions
In conclusion, we show for the first time that Fascin-1
expression significantly correlates with OS progression
and metastasis, revealing Fascin-1 as a potential prog-
nostic biomarker for poor outcome of OS patients. Our
data provide a rationale for future clinical investigations
of Fascin-1 as a therapeutic target in OS.
Additional file
Additional file 1: Figure S1. Kaplan-Meier analysis correlating the overall
survival of responders and non-responders patients to neoadjuvant therapy
with Fascin-1 immunohistochemical staining. The response to the therapy
was determined histologically on resected tumor specimens according to
Salzer-Kuntschik, and both responders and non-responders patients are
included in the analysis. To evaluate the relevance of our patient cohort,
we determined the correlation of chemotherapy response and the pres-
ence of metastases with the overall survival of the patients, since these
are known as key prognosis indicators in OS. As expected, non-
responders and metastases-positive patients had significantly shorter
overall survival than responders and metastases-free patients (not shown).
Furthermore, we determined the correlation of the overall survival of
non-responders and responders to neoadjuvant therapy with Fascin-1
staining. As shown in Fig. S1, we did not observe any significant differ-
ence in survival between Fascin-positive and Fascin-negative non-
responders patients. Kaplan-Meier analysis correlating immunohistochem-
ical staining of Fascin-1 in human OS tissues with overall survival of non-
responders and responders to neoadjuvant therapy. This analysis ex-
cluded specimens from patients who didn’t receive neoadjuvant therapy
(n = 3) or received incomplete therapy (n = 10). (PNG 66 kb)
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